Adial Pharmaceuticals Inc
(NASDAQ:ADIL)
$2.84
0.26[10.08%]
Last update: 8:59AM (Delayed 15-Minutes)
Get Real Time Here
$2.84
0[0.00%]
Open2.730Close2.780
Vol / Avg.14.299K / 157.700KMkt Cap3.459M
Day Range2.690 - 2.92052 Wk Range2.439 - 15.000

Adial Pharmaceuticals Stock (NASDAQ:ADIL), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$6.00

Lowest Price Target1

$6.00

Consensus Price Target1

$3.67

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
20100

Analyst Firms Making Recommendations1

  • Brookline Capital
  • Maxim Group
  • Litchfield Hills

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Adial Pharmaceuticals

All Ratings (4)

Upgrades (0)

Downgrades (1)

Initiations (2)

Q

What is the target price for Adial Pharmaceuticals (ADIL)?

A

The latest price target for Adial Pharmaceuticals (NASDAQ: ADIL) was reported by Brookline Capital on July 11, 2023. The analyst firm set a price target for $6.00 expecting ADIL to rise to within 12 months (a possible 111.27% upside). 1 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Adial Pharmaceuticals (ADIL)?

A

The latest analyst rating for Adial Pharmaceuticals (NASDAQ: ADIL) was provided by Brookline Capital, and Adial Pharmaceuticals reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for Adial Pharmaceuticals (ADIL)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adial Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adial Pharmaceuticals was filed on July 11, 2023 so you should expect the next rating to be made available sometime around July 11, 2024.

Q

Is the Analyst Rating Adial Pharmaceuticals (ADIL) correct?

A

While ratings are subjective and will change, the latest Adial Pharmaceuticals (ADIL) rating was a reiterated with a price target of $0.00 to $6.00. The current price Adial Pharmaceuticals (ADIL) is trading at is $2.84, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Adial Pharmaceuticals Stock (NASDAQ:ADIL), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$6.00

Lowest Price Target1

$6.00

Consensus Price Target1

$3.67

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
20100

Analyst Firms Making Recommendations1

  • Brookline Capital
  • Maxim Group
  • Litchfield Hills

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Adial Pharmaceuticals

All Ratings (4)

Upgrades (0)

Downgrades (1)

Initiations (2)

Q

What is the target price for Adial Pharmaceuticals (ADIL)?

A

The latest price target for Adial Pharmaceuticals (NASDAQ: ADIL) was reported by Brookline Capital on July 11, 2023. The analyst firm set a price target for $6.00 expecting ADIL to rise to within 12 months (a possible 111.27% upside). 1 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Adial Pharmaceuticals (ADIL)?

A

The latest analyst rating for Adial Pharmaceuticals (NASDAQ: ADIL) was provided by Brookline Capital, and Adial Pharmaceuticals reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for Adial Pharmaceuticals (ADIL)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adial Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adial Pharmaceuticals was filed on July 11, 2023 so you should expect the next rating to be made available sometime around July 11, 2024.

Q

Is the Analyst Rating Adial Pharmaceuticals (ADIL) correct?

A

While ratings are subjective and will change, the latest Adial Pharmaceuticals (ADIL) rating was a reiterated with a price target of $0.00 to $6.00. The current price Adial Pharmaceuticals (ADIL) is trading at is $2.84, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Adial Pharmaceuticals Stock (NASDAQ:ADIL), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$6.00

Lowest Price Target1

$6.00

Consensus Price Target1

$3.67

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
20100

Analyst Firms Making Recommendations1

  • Brookline Capital
  • Maxim Group
  • Litchfield Hills

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Adial Pharmaceuticals

All Ratings (4)

Upgrades (0)

Downgrades (1)

Initiations (2)

Q

What is the target price for Adial Pharmaceuticals (ADIL)?

A

The latest price target for Adial Pharmaceuticals (NASDAQ: ADIL) was reported by Brookline Capital on July 11, 2023. The analyst firm set a price target for $6.00 expecting ADIL to rise to within 12 months (a possible 111.27% upside). 1 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Adial Pharmaceuticals (ADIL)?

A

The latest analyst rating for Adial Pharmaceuticals (NASDAQ: ADIL) was provided by Brookline Capital, and Adial Pharmaceuticals reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for Adial Pharmaceuticals (ADIL)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adial Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adial Pharmaceuticals was filed on July 11, 2023 so you should expect the next rating to be made available sometime around July 11, 2024.

Q

Is the Analyst Rating Adial Pharmaceuticals (ADIL) correct?

A

While ratings are subjective and will change, the latest Adial Pharmaceuticals (ADIL) rating was a reiterated with a price target of $0.00 to $6.00. The current price Adial Pharmaceuticals (ADIL) is trading at is $2.84, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Adial Pharmaceuticals Stock (NASDAQ:ADIL), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$6.00

Lowest Price Target1

$6.00

Consensus Price Target1

$3.67

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
20100

Analyst Firms Making Recommendations1

  • Brookline Capital
  • Maxim Group
  • Litchfield Hills

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Adial Pharmaceuticals

All Ratings (4)

Upgrades (0)

Downgrades (1)

Initiations (2)

Q

What is the target price for Adial Pharmaceuticals (ADIL)?

A

The latest price target for Adial Pharmaceuticals (NASDAQ: ADIL) was reported by Brookline Capital on July 11, 2023. The analyst firm set a price target for $6.00 expecting ADIL to rise to within 12 months (a possible 111.27% upside). 1 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Adial Pharmaceuticals (ADIL)?

A

The latest analyst rating for Adial Pharmaceuticals (NASDAQ: ADIL) was provided by Brookline Capital, and Adial Pharmaceuticals reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for Adial Pharmaceuticals (ADIL)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adial Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adial Pharmaceuticals was filed on July 11, 2023 so you should expect the next rating to be made available sometime around July 11, 2024.

Q

Is the Analyst Rating Adial Pharmaceuticals (ADIL) correct?

A

While ratings are subjective and will change, the latest Adial Pharmaceuticals (ADIL) rating was a reiterated with a price target of $0.00 to $6.00. The current price Adial Pharmaceuticals (ADIL) is trading at is $2.84, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Adial Pharmaceuticals Stock (NASDAQ:ADIL), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$6.00

Lowest Price Target1

$6.00

Consensus Price Target1

$3.67

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
20100

Analyst Firms Making Recommendations1

  • Brookline Capital
  • Maxim Group
  • Litchfield Hills

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Adial Pharmaceuticals

All Ratings (4)

Upgrades (0)

Downgrades (1)

Initiations (2)

Q

What is the target price for Adial Pharmaceuticals (ADIL)?

A

The latest price target for Adial Pharmaceuticals (NASDAQ: ADIL) was reported by Brookline Capital on July 11, 2023. The analyst firm set a price target for $6.00 expecting ADIL to rise to within 12 months (a possible 111.27% upside). 1 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Adial Pharmaceuticals (ADIL)?

A

The latest analyst rating for Adial Pharmaceuticals (NASDAQ: ADIL) was provided by Brookline Capital, and Adial Pharmaceuticals reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for Adial Pharmaceuticals (ADIL)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adial Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adial Pharmaceuticals was filed on July 11, 2023 so you should expect the next rating to be made available sometime around July 11, 2024.

Q

Is the Analyst Rating Adial Pharmaceuticals (ADIL) correct?

A

While ratings are subjective and will change, the latest Adial Pharmaceuticals (ADIL) rating was a reiterated with a price target of $0.00 to $6.00. The current price Adial Pharmaceuticals (ADIL) is trading at is $2.84, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Adial Pharmaceuticals Stock (NASDAQ:ADIL), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$6.00

Lowest Price Target1

$6.00

Consensus Price Target1

$3.67

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
20100

Analyst Firms Making Recommendations1

  • Brookline Capital
  • Maxim Group
  • Litchfield Hills

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Adial Pharmaceuticals

All Ratings (4)

Upgrades (0)

Downgrades (1)

Initiations (2)

Q

What is the target price for Adial Pharmaceuticals (ADIL)?

A

The latest price target for Adial Pharmaceuticals (NASDAQ: ADIL) was reported by Brookline Capital on July 11, 2023. The analyst firm set a price target for $6.00 expecting ADIL to rise to within 12 months (a possible 111.27% upside). 1 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Adial Pharmaceuticals (ADIL)?

A

The latest analyst rating for Adial Pharmaceuticals (NASDAQ: ADIL) was provided by Brookline Capital, and Adial Pharmaceuticals reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for Adial Pharmaceuticals (ADIL)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adial Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adial Pharmaceuticals was filed on July 11, 2023 so you should expect the next rating to be made available sometime around July 11, 2024.

Q

Is the Analyst Rating Adial Pharmaceuticals (ADIL) correct?

A

While ratings are subjective and will change, the latest Adial Pharmaceuticals (ADIL) rating was a reiterated with a price target of $0.00 to $6.00. The current price Adial Pharmaceuticals (ADIL) is trading at is $2.84, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Adial Pharmaceuticals Stock (NASDAQ:ADIL), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$6.00

Lowest Price Target1

$6.00

Consensus Price Target1

$3.67

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
20100

Analyst Firms Making Recommendations1

  • Brookline Capital
  • Maxim Group
  • Litchfield Hills

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Adial Pharmaceuticals

All Ratings (4)

Upgrades (0)

Downgrades (1)

Initiations (2)

Q

What is the target price for Adial Pharmaceuticals (ADIL)?

A

The latest price target for Adial Pharmaceuticals (NASDAQ: ADIL) was reported by Brookline Capital on July 11, 2023. The analyst firm set a price target for $6.00 expecting ADIL to rise to within 12 months (a possible 111.27% upside). 1 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Adial Pharmaceuticals (ADIL)?

A

The latest analyst rating for Adial Pharmaceuticals (NASDAQ: ADIL) was provided by Brookline Capital, and Adial Pharmaceuticals reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for Adial Pharmaceuticals (ADIL)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adial Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adial Pharmaceuticals was filed on July 11, 2023 so you should expect the next rating to be made available sometime around July 11, 2024.

Q

Is the Analyst Rating Adial Pharmaceuticals (ADIL) correct?

A

While ratings are subjective and will change, the latest Adial Pharmaceuticals (ADIL) rating was a reiterated with a price target of $0.00 to $6.00. The current price Adial Pharmaceuticals (ADIL) is trading at is $2.84, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Adial Pharmaceuticals Stock (NASDAQ:ADIL), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$6.00

Lowest Price Target1

$6.00

Consensus Price Target1

$3.67

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
20100

Analyst Firms Making Recommendations1

  • Brookline Capital
  • Maxim Group
  • Litchfield Hills

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Adial Pharmaceuticals

All Ratings (4)

Upgrades (0)

Downgrades (1)

Initiations (2)

Q

What is the target price for Adial Pharmaceuticals (ADIL)?

A

The latest price target for Adial Pharmaceuticals (NASDAQ: ADIL) was reported by Brookline Capital on July 11, 2023. The analyst firm set a price target for $6.00 expecting ADIL to rise to within 12 months (a possible 111.27% upside). 1 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Adial Pharmaceuticals (ADIL)?

A

The latest analyst rating for Adial Pharmaceuticals (NASDAQ: ADIL) was provided by Brookline Capital, and Adial Pharmaceuticals reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for Adial Pharmaceuticals (ADIL)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adial Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adial Pharmaceuticals was filed on July 11, 2023 so you should expect the next rating to be made available sometime around July 11, 2024.

Q

Is the Analyst Rating Adial Pharmaceuticals (ADIL) correct?

A

While ratings are subjective and will change, the latest Adial Pharmaceuticals (ADIL) rating was a reiterated with a price target of $0.00 to $6.00. The current price Adial Pharmaceuticals (ADIL) is trading at is $2.84, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

Adial Pharmaceuticals Stock (NASDAQ:ADIL), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1

Buy

Highest Price Target1

$6.00

Lowest Price Target1

$6.00

Consensus Price Target1

$3.67

Analyst Rating Summary1

BuyOverweightHoldUnderweightSell
20100

Analyst Firms Making Recommendations1

  • Brookline Capital
  • Maxim Group
  • Litchfield Hills

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Adial Pharmaceuticals

All Ratings (4)

Upgrades (0)

Downgrades (1)

Initiations (2)

Q

What is the target price for Adial Pharmaceuticals (ADIL)?

A

The latest price target for Adial Pharmaceuticals (NASDAQ: ADIL) was reported by Brookline Capital on July 11, 2023. The analyst firm set a price target for $6.00 expecting ADIL to rise to within 12 months (a possible 111.27% upside). 1 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Adial Pharmaceuticals (ADIL)?

A

The latest analyst rating for Adial Pharmaceuticals (NASDAQ: ADIL) was provided by Brookline Capital, and Adial Pharmaceuticals reiterated their buy rating.

Q

When is the next analyst rating going to be posted or updated for Adial Pharmaceuticals (ADIL)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adial Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adial Pharmaceuticals was filed on July 11, 2023 so you should expect the next rating to be made available sometime around July 11, 2024.

Q

Is the Analyst Rating Adial Pharmaceuticals (ADIL) correct?

A

While ratings are subjective and will change, the latest Adial Pharmaceuticals (ADIL) rating was a reiterated with a price target of $0.00 to $6.00. The current price Adial Pharmaceuticals (ADIL) is trading at is $2.84, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.